Priorities and Recommendations to Make ALS a Livable Disease Emanating from the 2024 National Academies of Sciences, Engineering, and Medicine Report Living with ALS.
Review in Annals of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Ileana M Howard *Rehabilitation Care Services, VA Puget Sound Healthcare System, Seattle, WA, USA.
Suma Babu *Department of Neurology, Sean M. Healy and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Chelsey CarterSchool of Public Health, Yale University, New Haven, CT, USA.
Stacey A SakowskiDepartment of Neurology, University of Michigan, Ann Arbor, MI, USA.
Jerome E KurentDepartment of Neurology, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Merit E CudkowiczDepartment of Neurology, Sean M. Healy and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7075-1681
Eva L FeldmanDepartment of Neurology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-9162-2694
Funding
Access for All in ALS (ALL ALS) West Clinical Coordinating Center OT2NS136939 · NINDS · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI ROBERT P BOWSER, BRENT T HARRIS · 2023 to 2026
$76.5M
Access for All in ALS (ALL ALS) East Clinical Coordinating Center OT2NS136938 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Jinsy Andrews, Suma Babu · 2023 to 2026
$71.5M
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical TrialU01NS077179 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Merit E CUDKOWICZ, Aleksandar Videnovic · 2011 to 2026
$43.4M
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral SclerosisU01NS136020 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI BABU, SUMA, BERRY, JAMES DALE · 2023 to 2025
$33.0M
An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with PridopidineU01NS136021 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Suma Babu, James Dale Berry · 2023 to 2026
$29.6M
An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral SclerosisUF1NS131791 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI BABU, SUMA, BERRY, JAMES DALE · 2022 to 2022
$18.1M
Mapping the ALS Exposome to Gain New Insights into Disease Risk and PathogenesisR01ES030049 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BATTERMAN, STUART A, FELDMAN, EVA LUCILLE · 2020 to 2024
$3.5M
Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohortR01NS127188 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BATTERMAN, STUART A, FELDMAN, EVA LUCILLE · 2021 to 2024
$3.4M
RFA-TS-23-001: Establishing the Cohort for Occupational Risk and Prevention Studies for Amyotrophic Lateral Sclerosis (ALS CORPS)R01TS000344 · TS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FELDMAN, EVA LUCILLE, GOUTMAN, STEPHEN · 2023 to 2025
$1.5M
Linking long-term air pollution exposure with inflammation, ALS risk, and disease progressionR01TS000327 · TS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FELDMAN, EVA LUCILLE, GOUTMAN, STEPHEN · 2021 to 2023
$1.4M
ACL HHS R01TS000344ALS AssociationALS Finding a CureALS OneAmerican Academy of NeurologyATSDR CDC HHS R01 TS000327ATSDR CDC HHS R01 TS000344Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry R01TS000327Charles H. Abdalian, Jr. ALS Research FundMuscular Dystrophy AssociationNeuroNetwork for Emerging TherapiesNIEHS NIH HHS R01 ES030049NIH HHS 1OT2NS136938-1NIH HHS 1U01NS077179-01NIH HHS 1U01NS136020-01NIH HHS 1U01NS136021-01NIH HHS OT2NS136939NIH HHS R01ES030049NIH HHS R01NS127188NIH HHS UF1NS131791-01NINDS NIH HHS OT2 NS136938NINDS NIH HHS OT2 NS136939NINDS NIH HHS R01 NS127188NINDS NIH HHS U01 NS077179NINDS NIH HHS U01 NS136020NINDS NIH HHS U01 NS136021NINDS NIH HHS UF1 NS131791Scott L. PrangerThe Neurological Clinical Research InstituteThe Sean M. Healey & AMG Center for ALS
6 · The paper itself
Abstract
Amyotrophic lateral sclerosis (ALS) is a relentless, fatal neurodegenerative disease. The progressive loss of voluntary muscle function, diagnostic delays, lack of effective treatments, and challenges accessing multidisciplinary care and resources have tremendous impact on quality of life. The congressionally directed ALS committee of the National Academies of Science, Engineering, and Medicine, in their 2024 report "Living with ALS," recommends critical actions for specific United States stakeholders to make ALS a livable disease over the next decade. This review summarizes the context and recommendations of the report. Advocacy efforts are critical to make these recommendations a reality for the ALS community. ANN NEUROL 2024;96:1035-1039.
Indexed as
Amyotrophic Lateral SclerosisHumansQuality of LifeUnited States
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Priorities and Recommendations to Make ALS a Livable Disease Emanating from the 2024 National Academies of Sciences, Engineering, and Medicine Report Living with ALS. · full record | OpenQuestion